How will the 35% price discount by Merck/Samsung Bioepis on their infliximab biosimilar, compared with the reference, influence stakeholder uptake?
Infliximab-abda (Renflexis), biosimilar to Janssen Biotech tumor necrosis factor inhibitor infliximab (Remicade), is being introduced into the US market at a list price of $753.39, which represents a 35% discount off the current list price of Remicade. Merck and Samsung Bioepis have made a bold move by introducing the second biosimilar to Remicade at a significant discount.
Remicade and its 2 biosimilars, infliximab-abda and infliximab-dyyb (Inflectra) are long term treatments that are, for the most part, administered under the medical benefit.
Celltrion’s and Pfizer’s Inflectra has struggled to capture market share from Remicade due to factors such as offering a low discount (15%) off the originator’s list price and not being able to overcome effective contracting strategies and additional discounts provided by Janssen. Remicade erosion was targeted to be somewhere between 10%-15% and the erosion has been only about 5% in Q2 2017, which is less severe than expected.
In order to successfully capture more of Remicade’s US market share and $4.84 B in annual sales, Merck and Samsung Bioepsis have offered a 35% discount off the list price of Remicade. This discount, which is more than double Inflectra’s discount, will influence commercial insurers to evaluate the opportunity and then perhaps implement medical benefit (as well as pharmacy benefit) formulary changes to prefer Renflexis over Remicade. Additionally, this discount may encourage organizations that administer these drugs (ie, health systems) to begin utilizing and stocking up on Renflexis. Under the current Medicare Part B coding and reimbursement policy for biosimilars, providers will likely profit from a good portion of the 20% price difference between Renflexis and Inflectra, which share the same billing code.
The introduction of a second biosimilar, and future biosimilars, to Remicade along with a favorable management by insurers and utilization by organizations administering these drugs will help advance price competition, increase market share for biosimilars, and improve access for patients in the United States. We will see over the course of 2017 and 2018 whether the discount offered by Merck and Samsung was enough to influence insurers to prefer the biosimilar over the innovator.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.